Figure 2.

Overall survival (OS) after treatment with azacitidine ± DLI in 151 patients based on a scoring system including relapse type and time between allo-HSCT and diagnosis of relapse. One point was assigned for molecular relapse, while two points were given for diagnosis of hematologic relapse. An interval between transplant and relapse of ≥6 months was assigned with zero points, while for relapse within the first 6 months after transplant one point was given. As such, the model enables a stratification of patients into three distinct risk categories (favorable = 1 point, intermediate = 2 points, unfavorable = 3 points).